Description overdue on 11.08.2012

Arthrifuge . The principle is based on the oppression of the impact of the process of phagocytosis of the microcrystals of salts Uric acid , Lowering the rate of migration of leukocytes into an inflammation focus. Colchicine inhibits (partially or completely) the process of cell division in metaphase and anaphase stage, has antimitotic effects It prevents degranulation of neutrophils. The drug prevents the development of amyloidosis   by reducing education amyloid fibril . Highly effective form relieves attacks of acute gout. In 75% of patients had improvement of health in the first 12 hours of treatment. In 80% of patients recorded adverse reactions from the digestive system. Intravenous administration of the drug to avoid adverse reactions of the gastro-intestinal tract, to accelerate the onset of clinical effect. The probability of recurrent acute attacks of gout decreased and ¾ of patients with a daily intake of 1-2 mg of colchicine. The drug reduces the activity of the dopamine-beta-hydroxylase, can prevent acute attacks in patients with Familial Mediterranean fever . Patients with primary amyloidosis AL-colchicine increases life expectancy. At systemic sclerosis   the drug has a positive effect on the skin, reduces dryness, softens the skin. Colchicine is available in tablet dosage form.

Indications, contraindications:

Colchicine is prescribed for gout , Amyloidosis, inflammatory diseases in the ENT and dental practice, with Mediterranean fever , Phlebitis, scleroderma, chondrocalcinosis, gouty arthritis. The drug is not prescribed for severe disease of the digestive system, with neutropenia, the elderly, alcoholism, intolerance of the main component, with purulent infections, diseases of the bone marrow, liver and kidneys, pregnancy .

Side effect:

The digestive tract:   nausea, malabsorption , Increased liver enzymes, vomiting, loss of appetite, epigastric pain, diarrhea syndrome, vitamin B12 deficiency. Nervous system:   neuropathy, peripheral neuritis Depression. Bodies of blood:   thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia, leukopenia. The allergic response in the form of a morbilliform rash, hives . Local reactions manifested as necrosis of surrounding tissue irritation at the injection site. It is also noted myopathy, azoospermia , Irregularities in the renal system, temporary alopecia.

Overdose:

Manifested severe diarrhea, severe dehydration with a drop in blood pressure, epigastric pain, vomiting, nausea, hemorrhagic gastroenteritis , Respiratory depression, convulsions, oliguria, ascending paralysis, hematuria, decreased myocardial contractility. Rarely recorded the development of pulmonary infiltrates, acute renal failure, hepatocellular damage.   On the sixth day after the overdose, severe suppression of bone marrow hematopoiesis with the development of coagulopathy, thrombocytopenia, leukopenia. Treatment of patients is carried out in the poison control center. Currently no specific antidote is not developed. Requires control   electrolyte balance Normalization of blood gas holding antishock measures, conducting assisted ventilation, airway control. Hemodialysis has not proved its effectiveness.

Mode of application:

Colchicine is taken orally. Inflammation gout: the first day of therapy 3 times a day to 1 mg; the second and third day of therapy administered twice-daily 1 mg; the fourth day of treatment is shown receiving 1 mg in the evening. Perhaps an alternative treatment for pattern: initial dose of 1 mg, then move on to receive 0, 5-1, 5 mg, the interval between meals 2 hours prior to the disappearance of pain. Prevention of gout attacks: three months in the evening take 1 mg to effectively treat gout without tophi. The day is not more than 8 mg. The duration of therapy with amyloidosis sostavlyaet5 years, take daily 1-3 mg per day.

Special instructions:

Colchicine drug therapy requires regular clinical and hematology control . When you register side effects from the digestive tract drug colchicine cancel or reduce the dosage. By reducing platelet count lower than 100 thousand / ml, and the cells below 3tys / l of the drug to stabilize blood cancel. The treatment period may be a false positive reaction to the red blood cells and Hb in urine.

Drug Interactions:

The likelihood of myopathy increases in patients with pathology of the renal system, while receiving cyclosporine . Colchicine can be administered in combination therapy with drugs and erikozuricheskimi allopurinol . The drug enhances the efficiency and deprimiruyuschie sympathomimetic agents. Colchicine interferes with the absorption of cyanocobalamin. Thrombocytopenia and leukopenia developed while taking NSAIDs, and drugs that cause mielodepressiu . Drugs acidifying the urine and reduce protivopodagricakih cytostatic activity of the drug colchicine. The opposite effect is recorded upon receipt of alkalizing agents.